Arber DA et al. International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood 2022;140(11):1200-28. Abstract
Bernard E et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence 2022;1(7). Abstract
Brunner et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): Final analysis from a phase Ib study Blood 2021;138(Supplement 1):244. Abstract
Garcia JS et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. ASH 2021;Abstract 241.
Khoury JD et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36(7):1703-19. Abstract
Kröger N et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J Clin Oncol 2021;39(30):3318-27. Abstract
Nakamura R et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol 2021;39(30):3328-39. Abstract
Sallman DA et al. Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1B study results. EHA 2022;Abstract S166.
Savona MR et al. Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridine. MDS 2021;Abstract P48.
Wei A et al. Sabatolimab plus hypomethylating agents (HMAS) in patients (PTS) with high-/very high-risk myelodysplastic syndrome (HR/VHR-MDS) and acute myeloid leukemia (AML): Subgroup analysis of a phase 1 study. EHA 2021;Abstract S168.